Cytokeratin 2 [AE3]

GWB-DFC680

IgG1

Human

Cytokeratin 2 Storage

Electron Microscopy: Use at an assay dependent dilution. IHC-P: Use at an assay dependent dilution. WB: Use at a dilution of 1/1000 - 1/3000. Use BSA (instead of milk which contains some keratins) to block nonspecific binding to immunoblots. Predicted

Probably contributes to terminal cornification. Associated with keratinocyte activation proliferation and keratinization.

Expressed in the upper spinous and granular suprabasal layers of normal adult epidermal tissues from most body sites including thigh breast nipple foot sole penile shaft and axilla. Not present in foreskin squamous metaplasias and carcinomas. Expression in hypertrophic and keloid scars begins in the deepest suprabasal layer. Weakly expressed in normal gingiva and tongue however expression is induced in benign keratoses of lingual mucosa and in mild-to-moderate oral dysplasia with orthokeratinization. Developmental Stage: Synthesized during maturation of epidermal keratinocytes and localized in the upper intermediate cells of fetal skin. Earliest expression is at 10 weeks in the developing embryo in the presumptive nail bed of developing digits shifting to the proximal nail fold by 13. 5 weeks. At 12. 5 weeks detected in scattered cells of the intermediate layer of trunk skin. At 19. 3 weeks regional expression patterns were observed in upper intermediate keratinocytes of cheek trunk dorsal and ventral knee elbow and dorsal hand. Distal areas around the periumbilical region showed increased number of positive cells and by 15 weeks is expressed in small groups of cells in the fetal hair follicles.

There are two types of cytoskeletal and microfibrillar keratin: I (acidic; 40-55 kDa) and II (neutral to basic; 56-70 kDa).